Patent Attorney

Emma (Eunsun) Choi

Chief Managing Partner / Pharmacist

 

  • Phone: 02-6205-2225
  • Fax: 02-6205-0011
  • Email: eschoi@cnpip.co.kr
EDUCATION
  • Seoul National University, Seoul, Korea B.S., Pharmacy 1999
  • Queen Mary, University of London, London, UK MSc, Management of Intellectual Property 2006
  • University of California Berkeley, USA Law School, Visiting Scholar 2015

 

  • Handling licensing of pharmaceutical products such as diabetes, liver cancer and irritable bowel syndrome medicines

 

ADMISSIONS/QUALIFICATIONS
  • Qualified as the Korean Certified Valuation Analyst 2011
  • Admitted to the Korean Patent Bar 2001
  • Qualified as the Korean Pharmacist 1999
ACTIVITIES
  • Professor, SungKyunKwan University, School of Pharmacy
  • Committee on Investment, Korea Drug Development Fund (KDDF)
  • Expert Advisor, Korea Health Industry Development Institute (KHIDI)
EXPERIENCE

<2015-present CHOI & Partners Chief Managing Partner>

  • Handling patent actions such as invalidation actions, scope confirmation actions and infringement actions, especially for major pharmaceutical products such as Aloxi (palonosetron), Invega (paliperidone), Pradaxa (dabigatran), Cialis (tadalafil) and Pirespa (pirfenidone)
  • Preparing and prosecuting patent applications for pharmaceuticals, biologicals, medical devices, microbiomes, stem cells, cosmetics and chemicals
  • Providing expert opinions for IP strategies, technology transfer and clinical trial contracts
  • Reviewing contracts for pre-clinical trials, clinical trials and licensing
  • Handling licensing of pharmaceutical products such as diabetes, liver cancer and irritable bowel syndrome products

 

 

 

<2002-2003 KOREANA Patent Firm Patent Attorney>

  • Preparing and prosecuting patent applications for pharmaceuticals, cosmetics and chemicals
  • Analyzing patent validity and preparing expert opinions
  • Involving in litigations and preparing brief

<2006-2015 Kim & Chang Patent Attorney>

  • Handling patent actions, especially for major products of multinational pharmaceutical companies such as Plavix (Sanofi and BMS), Diovan (Novartis), Olmetec (Daiichi Sankyo), Micardis (boehringer ingelheim) and Avandia (GSK)
  • Handling compulsory licensing case for Fuzeon (Pfizer)
  • Providing strategic counseling for preventing generic entry on behalf of multinational pharmaceutical companies
  • Developing drug life cycle management in all aspects including patent portfolio, data exclusivity, and Korean drug insurance pricing system for the major drugs
  • Dealing with both the patent and regulatory issues for pharmaceutical products
  • Preparing and prosecuting patent applications for pharmaceuticals, biologicals, medical devices, and chemicals
  • Evaluating patents and reviewing license agreements
  • Reviewing IP status for M&A and technology transfer
  • Leading and handling patent listing under the patent linkage system as a lead member in the firm
  • Providing expert opinions and preparing responses to antitrust investigations of potential IP rights abuse
  • Providing educational presentation on the patent system, patent linkage system and Korean drug insurance pricing reduction system for the Korean branch of multinational pharmaceutical companies

Yongwoo Lee

Patent Attorney

 

  • Phone: 02-6205-2225
  • Fax: 02-6205-0011
  • Email: ywlee@cnpip.co.kr
Education
  • Korea University, College of Health Science, B.S.

 

Admissions/Qualifications
  • Admitted to the Korean Patent Bar

 

Professional Experience
  • CHOI & Partners, Patent Attorney (2016-Present)

 

Practice Area
  • Preparation and registration of patent applications

    Domestic/PCT applications for inventions such as compounds, medicinal usage/dosae patens, pharmaceutical compositions/formulations, natural products, strains, genetic engineering techniques, medical devices, location tracking devices.

  • FTO analysis and non-infringement strategy

    FTO analysis of original drug patents, review of patents in US Orange book, analysis of foreign lawsuits and FTO analysis of exhaust gas reduction device, establishment of avoidance strategy of blockbuster drug patents.

  • Patent validity review

    Validity evaluation of substance patents, composition patents, formulation patents and dosage patents of drugs.

  • Trial & litigation

    Trials and litigations to original drug patents including Pradaxa, Invega, Pirespa and Aloxi.

  • Patent Law/Case Study

    Research and analysis of international patent cases of drugs (KFDA, 2017), Domestic/international law and case study about Patent Term Extension (KIPO, 2017)

  • Government project

    Patent strategy consulting (KFDA, 2017/2018), Governmental R&D Patent strategy support program (KISTA, 2018)

  • Trademark, design, and copyright related work

    Application and registration of trademark, design, and copyright related works

Yunjin Kim

Patent Attorney

 

  • Phone: 02-6205-2225
  • Fax: 02-6205-0011
  • Email: yjkim@cnpip.co.kr
Education
  • Yonsei University, Chemical & Biomolecular Engineering, B.S.

 

Admissions/Qualifications
  • Admitted to the Korean Patent Bar

 

Professional Experience
  • CHOI & Partners, Patent Attorney (2019-Present)
  • Samsung Engineering Co., Ltd.(2013-2015)

 

Practice Area
  • Preparation and registration of patent applications
  • FTO analysis and non-infringement strategy
  • Patent validity review
  • Trademark, design, and copyright related work
위로이동